ATHE vs. AEZS, MBRX, GRTX, BFRI, AKTX, GHSI, ADIL, ELAB, PPBT, and MTEM
Should you be buying Alterity Therapeutics stock or one of its competitors? The main competitors of Alterity Therapeutics include Aeterna Zentaris (AEZS), Moleculin Biotech (MBRX), Galera Therapeutics (GRTX), Biofrontera (BFRI), Akari Therapeutics (AKTX), Guardion Health Sciences (GHSI), Adial Pharmaceuticals (ADIL), Elevai Labs (ELAB), Purple Biotech (PPBT), and Molecular Templates (MTEM). These companies are all part of the "pharmaceutical preparations" industry.
Alterity Therapeutics (NASDAQ:ATHE) and Aeterna Zentaris (NASDAQ:AEZS) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their institutional ownership, analyst recommendations, community ranking, profitability, valuation, risk, earnings, media sentiment and dividends.
Alterity Therapeutics has a beta of 0.94, suggesting that its share price is 6% less volatile than the S&P 500. Comparatively, Aeterna Zentaris has a beta of 1.57, suggesting that its share price is 57% more volatile than the S&P 500.
In the previous week, Aeterna Zentaris had 1 more articles in the media than Alterity Therapeutics. MarketBeat recorded 1 mentions for Aeterna Zentaris and 0 mentions for Alterity Therapeutics. Alterity Therapeutics' average media sentiment score of 1.48 beat Aeterna Zentaris' score of 0.00 indicating that Alterity Therapeutics is being referred to more favorably in the media.
Aeterna Zentaris received 416 more outperform votes than Alterity Therapeutics when rated by MarketBeat users. Likewise, 62.54% of users gave Aeterna Zentaris an outperform vote while only 60.00% of users gave Alterity Therapeutics an outperform vote.
2.1% of Alterity Therapeutics shares are held by institutional investors. Comparatively, 0.7% of Aeterna Zentaris shares are held by institutional investors. 38.8% of Alterity Therapeutics shares are held by insiders. Comparatively, 0.1% of Aeterna Zentaris shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.
Alterity Therapeutics has a net margin of 0.00% compared to Aeterna Zentaris' net margin of -368.01%. Alterity Therapeutics' return on equity of 0.00% beat Aeterna Zentaris' return on equity.
Alterity Therapeutics has higher earnings, but lower revenue than Aeterna Zentaris.
Alterity Therapeutics currently has a consensus price target of $7.00, indicating a potential upside of 201.72%. Aeterna Zentaris has a consensus price target of $15.00, indicating a potential upside of 650.00%. Given Aeterna Zentaris' higher possible upside, analysts plainly believe Aeterna Zentaris is more favorable than Alterity Therapeutics.
Summary
Alterity Therapeutics beats Aeterna Zentaris on 8 of the 14 factors compared between the two stocks.
Get Alterity Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for ATHE and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding ATHE and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Alterity Therapeutics Competitors List
Related Companies and Tools
